N@N

Molecular Insight Pharmaceuticals, Inc. : Molecular Insight Pharmaceuticals, Inc. to Announce Second Quarter Financial Results

^{Published on 2009-07-27 13:18:05, Last Modified on 2009-07-27 13:18:13 - Market Wire}
 

CAMBRIDGE, MA--(Marketwire - July 27, 2009) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: [ MIPI ]) announced today that it will release its second quarter 2009 financial results at 7:00 a.m. Eastern Time, Monday, August 10, 2009, followed by a conference call at 9:00 a.m. During the call, senior management of Molecular Insight will review the Company's financial results and provide an update on its clinical development programs.

Conference Call Details

To access the call on August 10, 2009 at 9:00 a.m., dial 1-888-713-4205 (or 1-617-213-4862 for international participants) at least five minutes prior to the start of the call. The participant pass code is 39474437. For one week following the call, an audio replay can be accessed by dialing 1-888-286-8010 (or 1-617-801-6888 for international callers) and using the pass code 77902304.

An audio webcast of the call will also be available in the "Investor Relations" section of the Company's website, [ www.molecularinsight.com ].

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: [ MIPI ]) is a Cambridge, Massachusetts-based biopharmaceutical company focused on the discovery and development of targeted molecular imaging and therapeutic radiopharmaceuticals in the emerging field of molecular medicine. These novel radiopharmaceuticals will provide important improvements in disease detection and staging and enable the delivery of radiation therapy to widespread metastatic cancers. The Company has focused the initial applications of its proprietary technologies in the areas of oncology and cardiology. Molecular Insight's lead diagnostic radiopharmaceutical product candidate, Zemiva™, is being developed for the diagnosis of myocardial ischemia, or insufficient blood flow to the heart, in the acute setting. The Company's diagnostic candidate, Trofex™, is in development initially for the detection of metastatic prostate cancer. Molecular Insight's molecular radiotherapeutic product candidates, Azedra™, Onalta™, and Solazed™, are also being developed for the treatment of various types of cancer. In addition, the Company's discovery efforts continue to identify early-stage candidates -- products of its in-house research and development expertise and the application of its proprietary platform technologies. For more information, visit [ http://www.molecularinsight.com ].